# US 2003/0215525 A1 · Heat stable antacid and antigas suspensions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215525 A1
- Document ID: US20030215525A1
- Status: Published application
- Kind: A1
- Application number: 10/304,837
- Filed: 2002-11-26
- Published: 2003-11-20
- Earliest claimed: 1998-09-21
- Inventors: Douglas S. Beyerle; John J. Dubek; Gerard P. McNally; Donald L. Hasenmayer; John Case; Abbie Gentry; Indu G. Shah
- Web page: https://patentgrep.com/patent/US20030215525A1

## CPC

- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 33/08: Oxides; Hydroxides
- A61K 33/10: Carbonates; Bicarbonates
- A61K 33/12: Magnesium silicate
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to heat stable liquid antacid and/or antigas preparations capable of being pasteurized in the temperature range of 60-100° C. comprising one or more acid neutralizing and/or antigas compounds in an aqueous liquid suspension consisting essentially of hydroxyethylcellulose as a suspending agent.

## Claims

### Claim 1

A pasteurized heat stable liquid antacid and/or antigas preparation comprising 200 mg-2000 mg/5 ml of an aluminum-containing acid neutralizing compound and/or 20-125 mg/5 ml antigas compound in an aqueous liquid suspension containing a preservative component in an amount that does not exceed 0.05% w/v and a suspending agent consisting essentially of hydroxyethylcellulose in an amount of from 1 mg-100 mg/5 ml and, optionally, one or more other pharmaceutically acceptable additives, said preparation having a viscosity of about 100 to 1000 cps at 25° C. and 70° C.

### Claim 2 (depends on 1)

A liquid antacid preparation according to claim 1, wherein the acid neutralizing compound is selected from calcium carbonate, dihydroxyaluminum sodium carbonate, magnesium carbonate, magnesium trisilicate, aluminum hydroxide and magnesium hydroxide and mixtures thereof.

### Claim 3 (depends on 1)

A liquid antacid preparation according to claim 1 wherein the acid neutralizing compound is calcium carbonate.

### Claim 4 (depends on 1)

A liquid antacid preparation according to claim 1 wherein the acid neutralizing compound is aluminum hydroxide gel.

### Claim 5 (depends on 1)

A liquid antacid preparation according to claim 1 wherein the acid neutralizing compound is dihydroxyaluminum sodium carbonate.

### Claim 6 (depends on 1)

A liquid antacid and/or antigas preparation according to claim 1 further comprising a preservative.

### Claim 7 (depends on 6)

A liquid antacid and/or antigas preparation according to claim 6 wherein the preservative is selected from butylparaben, methylparaben and propylparaben.

### Claim 8 (depends on 1)

A liquid antacid and/or antigas preparation according to claim 1 further comprising an antimicrobial adjuvant selected from the group consisting of propylene glycol in an amount greater than 2 weight percent and less than 15 weight percent, glycerin in an amount from about 15 to about 20 weight percent, and combinations of propylene glycol in an amount from about 3 to about 10 weight percent with glycerin in an amount from about 3 to about 10 weight percent based on the total weight of the preparation.

### Claim 9 (depends on 1)

A liquid antigas preparation according to claim 1 containing about 20 mg to about 500 mg of simethicone per 5 ml.

### Claim 10 (depends on 1)

A liquid antacid and/or antigas preparation according to claim 1, containing 1-100 mg/5 ml hydroxyethylcellulose.

### Claim 11 (depends on 1)

A liquid antacid preparation according to claim 1, further containing a pharmaceutically effective amount of a histamine H2 receptor antagonist.

### Claim 12 (depends on 11)

A liquid antacid preparation according to claim 11, wherein the histamine H2 receptor antagonist is selected from cimetidine, ranitidine, nizatidine and famotidine.

### Claim 13 (depends on 12)

A liquid antacid preparation according to claim 12, containing 100 mg to about 400 mg of cimetidine per dose.

### Claim 14 (depends on 12)

A liquid antacid preparation according to claim 12, containing 50 mg to about 150 mg of ranitidine per dose.

### Claim 15 (depends on 12)

A liquid antacid preparation according to claim 12, containing 5 mg to 40 mg of famotidine per 5 ml.

### Claim 16 (depends on 1)

A method for the treatment of a gastrointestinal disorder in a human in which acid neutralization and/or antigas treatment is desired which comprises administering to said human an effective amount of a liquid antacid and/or antigas composition of claim 1.

### Claim 17 (depends on 11)

A method for the treatment of a gastrointestinal disorder in a human in which acid neutralization is desired which comprises administering to said human an effective amount of a liquid antacid composition of claim 11.

### Claim 18 (depends on 16)

A method according to claim 16 wherein the gastrointestinal disorder is selected from the group consisting of acid indigestion, heartburn, dyspepsia, sour stomach, and reflux esophagitis.

### Claim 19

In a method for the terminal sterilization by pasteurization in the temperature range of 60-100° C., of liquid antacid and /or antigas preparations containing a suspending agent, the improvement which comprises increasing the flow rate by using hydroxyethylcellulose as the suspending agent.

### Claim 20

A pasteurized heat stable liquid antacid and/or antigas preparation comprising 200 mg-2000 mg/5 ml of an aluminum-containing acid neutralizing compound and/or 20-125 mg/5 ml antigas compound in an aqueous liquid suspension containing a preservative component in an amount that does not exceed 0.05% w/v and a suspending agent capable of being pasteurized without gelling, said preparation having a viscosity of about 100 to 1000 cps at 25° C. and 70° C.

### Claim 21

A method for preparing a liquid antacid and/or antigas preparation comprising providing the liquid antacid and/or antigas preparation containing a suspending agent, homogenizing the liquid antacid and/or antigas preparation and pasteurizing the liquid antacid and/or antigas preparation in a temperature range of 60-100° C., wherein the suspending agent is hydroxyethylcellulose, and after said pasteurizing said preparation has a viscosity of about 100 to 1000 cps at 25° C. and 70° C.
